MONTREAL, September 01, 2026--22 influential Canadians have signed an open letter calling on leaders from all sectors to join ...
Xentria, Inc., a clinical-stage biotherapeutics company, today announced its proposed next-stage clinical development plan for XTMAB-16, an investigational anti-tumor necrosis factor alpha, being ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results